Chemotherapy-Free Options Remain Unmet Need in Colorectal Cancer
Zev A. Wainberg, MD, explains the importance of having a chemotherapy-free option available for patients with colorectal cancer.
Zev A. Wainberg, MD, assistant professor of Medicine at the University of California Los Angeles, explained the importance of having a chemotherapy-free option available for patients with colorectal cancer.
Currently, 2 chemotherapy regimens are widely used as treatment of patients with colorectal cancer, including the FOLFIR regimen (irinotecan, fluorouracil (5-FU), and folinic acid [leucovorin]) and the FOLFIRNOX regimen (Folinic acid, fluorouracil, irinotecan, and oxaliplatin). Wainberg says that many oncologists are now hoping for individualized options.
One agent, regorafenib (Stivarga) is FDA approved for the treatment of colorectal cancer, but beyond regorafenib, there are no FDA approved options. There is also limited clinical trial data regarding the efficacy and safety of investigational targeted therapies for the treatment of this population.
